Search for: "Eli Lilly "
Results 1601 - 1620
of 2,131
Sort by Relevance
|
Sort by Date
4 Nov 2009, 4:03 am
Stakeholders react to draft report (IP Watch) US: District Court S D New York denies motions to dismiss in gene patent case: Association for Molecular Pathology v USPTO (Inventive Step) (Patent Docs) (Patent Baristas) (Ars Technica) (The IP Factor) (Patently-O) (IP Watch) Products Ceclor (Cefaclor) - Canada: Eli Lilly successful in patent infringement action against Apotex (Pharmacapsules @ Gowlings) Oxytrol (Oxybutynin) - US: Watson and Barr settle patent litigation (SmartBrief)… [read post]
4 Nov 2009, 4:03 am
Stakeholders react to draft report (IP Watch) US: District Court S D New York denies motions to dismiss in gene patent case: Association for Molecular Pathology v USPTO (Inventive Step) (Patent Docs) (Patent Baristas) (Ars Technica) (The IP Factor) (Patently-O) (IP Watch) Products Ceclor (Cefaclor) – Canada: Eli Lilly successful in patent infringement action against Apotex (Pharmacapsules @ Gowlings) Oxytrol (Oxybutynin) – US: Watson and Barr settle patent… [read post]
4 Nov 2009, 2:03 am
Food and Drug Administration has issued a warning about possible kidney problems associated with the use of Byetta, a diabetes drug marketed by Amylin Pharmaceuticals Inc. and Eli Lilly & Co. [read post]
4 Nov 2009, 2:03 am
Food and Drug Administration has issued a warning about possible kidney problems associated with the use of Byetta, a diabetes drug marketed by Amylin Pharmaceuticals Inc. and Eli Lilly & Co. [read post]
3 Nov 2009, 2:35 pm
On November 2, 2009 Amylin Pharmaceuticals, Inc., and Eli Lilly and Company issued their joint statement in response to the FDA on BYETTA® (exenatide) injection. [read post]
2 Nov 2009, 11:04 pm
Amylin Pharmaceuticals Inc. and Eli Lilly & Co. said safety warnings were strengthened for their diabetes drug Byetta relating to the risks of pancreatitis and the medicine's use by patients with severe kidney disease. [read post]
2 Nov 2009, 7:05 am
" This comes on the heals of the similar scandal at Eli Lilly over Zyprexa, leading to a $1.4 billion payment, and Pfizer's $2.3 billion payment, which includes "a record $1.195 billion criminal fine, mostly over its painkiller Bextra, which has been withdrawn from the market. [read post]
1 Nov 2009, 11:19 pm
Earlier this year, Eli Lilly & Company paid $1.4 billion over its marketing of Zyprexa, another antipsychotic drug. [read post]
27 Oct 2009, 7:59 am
" And South Carolina's Attorney General has settled with Eli Lilly for $45 million - the largest settlement so far of the 44 states that have sued the company for improperly marketing Zyprexa for off-label use, causing injuries costing taxpayers boatloads of money. [read post]
26 Oct 2009, 5:36 am
The State Newspaper included more details about the settlement between South Carolina and drug manufacturer Eli Lilly with regard to allegations of off-label marketing for the drug Zyprexa. [read post]
25 Oct 2009, 10:18 am
Hasbro, Blackrock, Pfizer, Wells Fargo, Eli Lilly, Morgan Stanley, Deutsche Bank, Gannett, Merck, UPS, McDonald's, Microsoft, American Express, and Amazon, among others. [read post]
21 Oct 2009, 6:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) – US: Shire announces settlement… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz over… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz over… [read post]
18 Oct 2009, 9:17 pm
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. [read post]
9 Oct 2009, 10:30 am
Eli Lilly (civil case) [uploaded: 10/09/2009] [read post]
8 Oct 2009, 6:08 am
The action brought by Attorney General Henry McMaster against drug manufacturer Eli Lilly has reportedly settled. [read post]
8 Oct 2009, 6:05 am
Teva Pharmaceuticals USA, Inc (Patent Docs) (Patent Baristas) (GenericsWeb) Trileptal (Oxacarbazepine) - Israel Patent Office prevents Novartis from submitting empirical evidence in patent opposition case (IP Factor) Vesicare (Solifenacin) – US: Astellas files patent infringement lawsuit against Teva over generic Vesicare (GenericsWeb) Zyprexa (Olanzapine) – Canada: Teva Novopharm invalidates Eli Lilly’s Canadian patent for Olanzapine (IP Factor)… [read post]
8 Oct 2009, 5:40 am
Eli Lilly (Written Description): Ariad has filed its opening brief in the en banc Federal Circuit challenge to the statutory basis for a written description requirement that is separate and distinct from enablement requirement. [read post]
2 Oct 2009, 7:14 am
Tax gross-ups were a contributing factor at Sandisk and Equifax, and helped fuel more than 20 percent opposition at AT&T, Agilent Technologies, AK Steel, CIT Group, and Eli Lilly. [read post]
